Please Note: This trial is no longer enrolling new participants
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab in Patients with Inoperable Stage III Non-small Cell Lung Cancer: The Indiana Trial
| Protocol No. | CTO-IUSCCC-0749 | Scope | Local |
|---|---|---|---|
| Principal Investigator | Nasser Hanna | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase II |
